Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 11/20 | 0.49 |
| ▸ | JAK2 | O60674 | 7/20 | 0.48 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.45 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2788183 | 0.91 | JAK1 (0.49) | JAK1JAK2MAP3K5ACKR3TYK2 | |
| SCHEMBL12341929 | 0.90 | JAK1 (0.49) | JAK1JAK2MAP3K5ACKR3HDAC1 | |
| SCHEMBL2787611 | 0.90 | JAK2 (0.57) | JAK1JAK2MAP3K5 | |
| SCHEMBL3020912 | 0.88 | JAK1 (0.47) | JAK1JAK2MAP3K5ACKR3HDAC1 | |
| SCHEMBL2787919 | 0.83 | KDM4E (0.47) | JAK1JAK2MAP3K5 | |
| SCHEMBL2772557 | 0.83 | MAP3K5 (0.51) | JAK1JAK2MAP3K5ACKR3TYK2 | |
| SCHEMBL2789350 | 0.83 | MAP3K5 (0.49) | JAK1JAK2MAP3K5ACKR3TYK2 | |
| SCHEMBL2786888 | 0.83 | MAP3K5 (0.66) | JAK1JAK2MAP3K5 | |
| SCHEMBL2787694 | 0.81 | JAK1 (0.53) | JAK1JAK2MAP3K5 | |
| SCHEMBL3020907 | 0.81 | MAP3K5 (0.49) | JAK1JAK2MAP3K5ACKR3TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2181112-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | Merck Serono S.A. (CH) | 2010-05-05 | — | — | EP | claimed |
| WO-2009027283-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | MERCK SERONO S.A. (CH) | 2009-03-05 | — | — | WO | claimed |
| US-20100197681-A1 | Triazolopyridine Compounds and Their Use as Ask Inhibitors | MERCK SERONO SA (CH) | 2010-08-05 | — | — | US | disclosed |
| EP-2181112-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | Merck Serono S.A. (CH) | 2010-05-05 | — | — | EP | disclosed |
| WO-2009027283-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | MERCK SERONO S.A. (CH) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197681-A1 | Triazolopyridine Compounds and Their Use as Ask Inhibitors | MAP3K5, MAPKAPK5, MAP3K9 | JAK1 229/4885JAK2 228/4885MAP3K5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.